KPTI – karyopharm therapeutics inc. (US:NASDAQ)

News

Karyopharm Therapeutics (NASDAQ:KPTI) was given a new $12.00 price target on by analysts at The Goldman Sachs Group, Inc..
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Karyopharm to Participate in Baird's Biotech Discovery Series
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com